Lanreotide
Lanreotide, a peptide. Cyclic octapeptide somatostatin analog (D-βNal substituted for D-Phe vs. octreotide) with SSTR2 and SSTR5 agonist… Subcutaneous half-life 22 d.
Cyclic octapeptide somatostatin analog (D-βNal substituted for D-Phe vs. octreotide) with SSTR2 and SSTR5 agonist activity. Autogel is a supersaturated aqueous formulation that forms an extended-release deep-SC depot — no oil vehicle or polymer microspheres required. Indications mirror octreotide: acromegaly (GH / IGF-1 suppression), functional NET symptom control, anti-proliferative effect (CLARINET trial — PFS benefit in non-functioning midgut + pancreatic NET).
PK describes the AUTOGEL DEPOT, not immediate-release — the two are different drug products. Antonijoan 2004 (PMID:15099442), 24 healthy volunteers, deep SC Autogel 40 mg, verbatim "mean apparent elimination half-life was 21.63 +/- 9.42 and 22.01 +/- 9.87 days" (40 mg arm = 519 h; the stored 600 h appears in no paper). V/F 18.3 L from Buil-Bruna 2016 (PMID:26416534), 290 GEP-NET patients, verbatim "The estimated apparent volume of distribution was 18.3 L"; F is pinned to 1 because that volume is apparent. ka and the stored F 0.75 dropped 2026-09-06: no absorption constant is published, and the cited paper reports only RELATIVE bioavailability (0.93/0.82 vs immediate-release SC), not the absolute F a model consumes. For contrast, the immediate-release IV profile is t1/2 1.32 h and Vss 0.172 L/kg (PMID:10579475) — do not mix it with these depot values.
Pharmacokinetics
- Subcutaneous — t½ 21.6 d · F 100% · Vd 18.3 L
Sources: PMID:15099442, PMID:26416534, PMID:10579475